The theoretical role of sigma receptors in psychosis has led to the discovery of selective sigma receptor ligands as potential antipsychotic agents. BMY 14802 is a sigma receptor ligand (IC50: 112 nM for (+)-[3H]-3-PPP).

In vitro: BMY 14802 has its most potent binding at the sigma binding site, with some degree of serotonin subtype 1A and negligible dopamine receptor binding [1].

In vivo: BMY 14802 is atypical of standard neuroleptics in that it does not induce catalepsy in rats. In addition, it has been shown to have efficacy in animal models of psychosis [1].

105565-55-7

C18H23ClF2N4O

384.85

BMY 14802 hydrochloride;BMY-14802 hydrochloride

H2O:<9.62mg/ml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years